ThermoGenesis Holdings (NSDQ:THMO) announced today that it filed patent applications for its point-of-care COVID-19 antibody detection device.
Rancho Cordova, Calif.-based ThermoGenesis’ device is designed to improve the speed and accuracy of lateral flow immunoassays (LFIA) in detecting COVID-19 IgM and IgG antibodies from a single drop of blood.
In a news release, ThermoGenesis chief technology officer Phil Coelho described the LFIA reader as a device that will enable the user to slide the test cartridge into a portable reader and receive an instant readout that can be immediately recorded into a corporate database or cloud-based web portal to offer insight into the spread of COVID-19 seropositivity in real-time.
“Today’s LFIAs, in certain cases, are challenging for untrained users to properly read when results are indicated by weakly stained bands,” Coelho said. “Variances among patients, if not read properly, could gener…